Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 10:01 am Purchase |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 4,450,885 9.990% |
2,138,685 (+92.50%) |
Filing History |
| 2024-02-14 09:58 am Purchase |
2023-12-31 | 13G | 89bio, Inc. ETNB |
BIOTECHNOLOGY VALUE FUND L P | 7,568,480 7.800% |
4,047,354 (+114.94%) |
Filing History |
| 2024-02-14 09:56 am Unchanged |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:54 am Purchase |
2023-12-31 | 13G | GH Research PLC GHRS |
BIOTECHNOLOGY VALUE FUND L P | 10,400,158 19.990% |
1,125,000 (+12.13%) |
Filing History |
| 2024-02-14 09:52 am Unchanged |
2023-12-31 | 13G | Galmed Pharmaceuticals Ltd. GLMD |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 09:50 am Purchase |
2023-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA |
BIOTECHNOLOGY VALUE FUND L P | 3,479,043 5.300% |
1,023,954 (+41.71%) |
Filing History |
| 2024-02-14 09:47 am Purchase |
2023-12-31 | 13G | Ikena Oncology, Inc. IKNA |
BIOTECHNOLOGY VALUE FUND L P | 4,769,164 9.900% |
2,266,093 (+90.53%) |
Filing History |
| 2024-02-14 09:45 am Sale |
2023-12-31 | 13G | iTeos Therapeutics, Inc. ITOS |
BIOTECHNOLOGY VALUE FUND L P | 1,259,476 3.500% |
-551,359 (-30.45%) |
Filing History |
| 2024-02-14 09:43 am Purchase |
2023-12-31 | 13G | Janux Therapeutics, Inc. JANX |
BIOTECHNOLOGY VALUE FUND L P | 4,579,818 9.900% |
472,873 (+11.51%) |
Filing History |
| 2024-02-14 09:41 am Sale |
2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-990,000 (Position Closed) |
Filing History |
| 2024-02-14 09:39 am Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 7,373,228 9.900% |
3,572,245 (+93.98%) |
Filing History |
| 2024-02-14 09:37 am Purchase |
2023-12-31 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 24,435,632 9.980% |
8,286,453 (+51.31%) |
Filing History |
| 2024-02-14 09:35 am Sale |
2023-12-31 | 13G | Merus N.V. MRUS |
BIOTECHNOLOGY VALUE FUND L P | 2,752,420 4.800% |
-226,000 (-7.59%) |
Filing History |
| 2024-02-14 09:33 am Purchase |
2023-12-31 | 13G | Molecular Templates, Inc. MTEM |
BIOTECHNOLOGY VALUE FUND L P | 537,426 9.990% |
537,426 (New Position) |
Filing History |
| 2024-02-14 09:31 am Purchase |
2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 5,763,948 9.990% |
738,048 (+14.68%) |
Filing History |
| 2024-02-14 09:28 am Sale |
2023-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,938,851 (Position Closed) |
Filing History |
| 2024-02-14 09:26 am Sale |
2023-12-31 | 13G | Revolution Medicines, Inc. RVMD |
BIOTECHNOLOGY VALUE FUND L P | 5,981,212 3.600% |
-1,574,376 (-20.84%) |
Filing History |
| 2024-02-14 09:24 am Purchase |
2023-12-31 | 13G | Tyra Biosciences, Inc. TYRA |
BIOTECHNOLOGY VALUE FUND L P | 2,739,595 6.400% |
267,268 (+10.81%) |
Filing History |
| 2024-02-14 09:22 am Sale |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,302,094 (Position Closed) |
Filing History |
| 2024-02-14 09:20 am Purchase |
2023-12-31 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 2,617,402 9.990% |
2,617,402 (New Position) |
Filing History |